Halozyme Therapeutics, Inc. (HALO) Stock Price
HALOStock
$121.84+82.18%52W
Market Cap$13.83B
P/E43.64x
PEG Ratio1.42
Div yield—
Beta0.93
HALO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)71.11%
Price vs S&P 500 (4W)10.65%
PEG Ratio1.42
VGM Score67.38
P/E Ratio (Annual)43.64x
HALO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.82 | $2.28 | +25.53%(+$0.46) | |
| Q1 2026 | $1.52 | $1.60 | +5.26%(+$0.08) | |
| Q4 2025 | $2.20 | -$0.24 | -110.92%(-$2.44) | |
| Q3 2025 | $1.63 | $1.72 | +5.51%(+$0.09) | |
| Q2 2025 | $1.27 | $1.54 | +21.45%(+$0.27) |
HALO Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.75
3.75
3.88
4.00
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
| TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics develops oncology therapies that target human enzymes to alter tumor progression. The company advances its pipeline through both internal development and partnerships with biopharmaceutical companies to commercialize its proprietary technology. Operations are primarily US-based with minimal international assets.